LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Lista de Ações・MannKind Corp

MannKind Corp

Fechado

SetorSaúde

3.39 -3.42

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.38

Máximo

3.44

Indicadores-chave
By Trading Economics
Rendimento	-671K -17M
Vendas	-22M 90M
P/E Médio do Setor	140.5 49.888
EPS	-0.02
Margem de lucro	-18.431
Funcionários	591
EBITDA	5.9M 3.4M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+139.71% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	223M 1.1B
Abertura anterior	6.81
Fecho anterior	3.39

Sentimento de Notícias

By Acuity

15%

85%

18 / 344 Ranking em Healthcare

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2026, 19:20 UTC

Grandes Movimentos do Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 de jun. de 2026, 21:27 UTC

Ganhos

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 20:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 de jun. de 2026, 20:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 de jun. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 19:26 UTC

Conversa de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 de jun. de 2026, 19:10 UTC

Conversa de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 de jun. de 2026, 19:03 UTC

Conversa de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 de jun. de 2026, 18:59 UTC

Conversa de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 de jun. de 2026, 18:47 UTC

Conversa de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 de jun. de 2026, 18:34 UTC

Conversa de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 de jun. de 2026, 18:33 UTC

Aquisições, Fusões, Aquisições de Empresas

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 de jun. de 2026, 17:50 UTC

Ganhos

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 de jun. de 2026, 17:27 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 de jun. de 2026, 16:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

5 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

5 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2026, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 de jun. de 2026, 15:26 UTC

Conversa de Mercado

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 de jun. de 2026, 15:25 UTC

Ganhos

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 de jun. de 2026, 15:16 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de jun. de 2026, 15:16 UTC

Conversa de Mercado

Zcash Tumbles After Exploit Found -- Market Talk

5 de jun. de 2026, 15:09 UTC

Conversa de Mercado

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 de jun. de 2026, 15:07 UTC

Conversa de Mercado

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 de jun. de 2026, 15:05 UTC

Conversa de Mercado

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

139.71% parte superior

Previsão para 12 meses

Média 8.15 USD 139.71%

Máximo 11 USD

Mínimo 4.75 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

18 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.